Indivior PLC (LSE:INDV) — Market Cap & Net Worth
Market Cap & Net Worth: Indivior PLC (INDV)
Indivior PLC (LSE:INDV) has a market capitalization of $18.79 Million (GBX154.47 Billion) as of August 7, 2026. Listed on the LSE stock exchange, this UK-based company holds position #25317 globally and #266 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Indivior PLC's stock price GBX1238.00 by its total outstanding shares 124770000 (124.77 Million). See Indivior PLC capex to cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
Indivior PLC Market Cap History: 2015 to 2025
Indivior PLC's market capitalization history from 2015 to 2025. Data shows growth from $13.78 Million to $18.79 Million (1.92% CAGR).
Index Memberships
Indivior PLC is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE All-Share
FTAS
|
$72.47 Billion | 0.03% | #196 of 573 |
|
FTSE 350
FTLC
|
$72.05 Billion | 0.03% | #193 of 350 |
|
FTSE 350 Pharmaceuticals & Biotechnology
NMX4570
|
$3.29 Billion | 0.57% | #4 of 6 |
Weight: Indivior PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Indivior PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Indivior PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Indivior PLC's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
7.77x
Indivior PLC's market cap is 7.77 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $13.78 Million | $1.01 Billion | $228.00 Million | 0.01x | 0.06x |
| 2016 | $22.48 Million | $1.06 Billion | $35.00 Million | 0.02x | 0.64x |
| 2017 | $30.98 Million | $1.09 Billion | $58.00 Million | 0.03x | 0.53x |
| 2018 | $8.53 Million | $1.00 Billion | $275.00 Million | 0.01x | 0.03x |
| 2019 | $2.96 Million | $785.00 Million | $134.00 Million | 0.00x | 0.02x |
| 2020 | $8.26 Million | $647.00 Million | -$148.00 Million | 0.01x | N/A |
| 2021 | $19.51 Million | $791.00 Million | $205.00 Million | 0.02x | 0.10x |
| 2022 | $28.12 Million | $901.00 Million | -$53.00 Million | 0.03x | N/A |
| 2023 | $17.99 Million | $1.09 Billion | $2.00 Million | 0.02x | 8.99x |
| 2024 | $15.55 Million | $1.19 Billion | $2.00 Million | 0.01x | 7.77x |
Competitor Companies of INDV by Market Capitalization
Companies near Indivior PLC in the global market cap rankings as of August 7, 2026.
Key companies related to Indivior PLC by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #541 globally with a market cap of $49.98 Billion USD ( CN¥341.53 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #551 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #625 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #509 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #541 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $49.98 Billion | CN¥53.54 |
| #551 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $44.04 |
| #625 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.20 |
Indivior PLC Historical Marketcap From 2015 to 2025
Between 2015 and today, Indivior PLC's market cap moved from $13.78 Million to $ 18.79 Million, with a yearly change of 1.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | GBX18.79 Million | +20.90% |
| 2024 | GBX15.55 Million | -13.59% |
| 2023 | GBX17.99 Million | -36.02% |
| 2022 | GBX28.12 Million | +44.12% |
| 2021 | GBX19.51 Million | +136.21% |
| 2020 | GBX8.26 Million | +178.97% |
| 2019 | GBX2.96 Million | -65.29% |
| 2018 | GBX8.53 Million | -72.48% |
| 2017 | GBX30.98 Million | +37.81% |
| 2016 | GBX22.48 Million | +63.19% |
| 2015 | GBX13.78 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 23rd, 2026 the market cap of Indivior PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $18.79 Million USD |
| MoneyControl | $18.79 Million USD |
| MarketWatch | $18.79 Million USD |
| marketcap.company | $18.79 Million USD |
| Reuters | $18.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Indivior PLC
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly … Read more